CURRICULUM VITAE

George Christopher Cunningham

Education:

B.S.	University of San Francisco (4-year scholarship)
Post Graduate	University of Southern California (scholarship) University of California, Berkeley Research Assistant in Biochemistry
M.D.	University of California, Los Angeles University of California, Los Angeles Intern in Department of Pediatrics Children's Hospital of the East Bay Resident in Pediatrics Children's Hospital of the East Bay Research Staff Fellow
M.P.H.	School of Public Health, University of California, Berkeley

Physician and Surgeon, Board of Medical Examiners, State of California

Clinical Instructor Pediatrics UCSF
Clinical Instructor Pediatrics UC Davis
Lecturer, School of Public Health UC Berkeley

Memberships:

Diplomate, American Board of Pediatrics

Fellow, American Academy of Pediatrics (Served on Indian Health Committee and Government Relations Title V Committee and Elected to Committee of the Section of Community Pediatrics)

Member, American College of Medical Genetics, ACMG Committee on Professional Practices, Chair, ACMG Committee on Public Health Genetics

Member, American Society of Human Genetics

Member, The Society for the Study of Inborn Errors of Metabolism

Member, International Society for Neonatal Screening

Associate Pediatrician, Department of Pediatrics, UCSF Medical Center

Member, Coalition of State Genetic Coordinators (Treasurer)

Member, Association of State and Territorial Public Health Laboratory Directors
Committee on Standardization

Chairman, American College of Medical Genetics Committee on Public Health Genetics

Member, Federal Food and Drug Administration Molecular and Clinical Genetics Devices Panel of the Medical Device Advisory Committee, Office of Device Evaluation, Center for Devices and Radiological Health

Emeritus Staff, Children's Hospital Oakland

Past and Present Consultative Appointments:

International Down Syndrome Committee

International Association of Bioethics

Office of Technology Assessment U.S. Senate, 1986-87

American Academy of Pediatrics Services Development Committee

National Research Council

Children's Defense Fund

Advisory Board, California Congress of Parents and Teachers, Inc.

Westinghouse Health Systems, IPO Consultant, 1981

Institute of Medicine

Council of State Governments

New York Committee on Life and the Law

National Newborn Screening and Genetic Resource Center

Awards:

California Rural Indian Health Board
Award for Outstanding Services to California Indians, 1971

California Association for Maternal and Child Health
Leadership Award, June 1974

California Human Services Organization
Award for Outstanding Human Services Administration, May 10, 1975

California Parents and Teachers Association, Inc.
Certification of Appreciation for Services to Children and Youth of California, May 1976

California Dietitians Award, May 12, 1978
Meritorious Service to Mothers and Children

Children's Medical Center of Northern California
Recognition Award for Contributions to Research in Children's Health, November 1984

American Physician Executives
Innovation Award for Maternal Serum Alpha Fetoprotein Program, April 1993

Work Experience:

1966-68	Chief, Hereditary Defects Unit, Bureau of Maternal and Child Health, California State Department of Public Health, Berkeley
Jan. 1969	Chief, Maternal and Child Health Branch, California State Department of Health, Sacramento
Aug. 1977	Chief, Genetic Disease Section, California State Department of Health Services
April 1980	Chief, Maternal and Child Health Branch, California Department of Health Services, Berkeley
Feb. 1981-Present	Chief, Genetic Disease Branch, California State Department of Health Services, Berkeley

Reviewer of Articles for:

Journal of Medical Screening
Prenatal Diagnosis
Obstetrics and Gynecology
New England Journal of Medicine

Publications:

1. Tolbutamide Tolerance in Hypoglycemic Children. G. Cunningham. Am. J. Dis. Child., 107:414-423, April 1964.

2. Nephrotic Syndrome with Hypercatabolic Hypoalbuminemia. G. Cunningham and M. Holliday. Proceedings, 13th Annual Meeting of the Western Society of Pediatric Research, November 1965.

3. Phenylketonuria - Early Detection, Diagnosis and Treatment. G. Cunningham. California Medicine, 105:1-7, July 1966.

4. After PKU What: Estimate Criteria and Recent Data. G. Cunningham. Public Health Laboratory, 25(4):118-125, July 1967.

5. Two Years of PKU Testing in California: The Role of the Laboratory. G. Cunningham. California Medicine, 110:11-16, January 1969.

6. Causes for High Phenylalanine with Normal Tyrosine in Newborn Screening Programs. J. Berman, G. Cunningham, R. Day, et al. Am. J. Dis. Child., 117:54-65, January 1969.

7. Phenylalanine Tolerance Tests. G. Cunningham, R.W. Day, J. Berman, and D.Y. Hsia. Am. J. Dis. Child., 117:626-635, June 1969.

8. Biochemical Screening Programs and Problems. G. Cunningham. Proceedings, Bi-Regional Institute on Earlier Recognition of Handicapping Conditions of Childhood, U.C. Berkeley School of Public Health, pp. 37-41, May 3-7, 1970.

9. Phenylketonuria Testing - Its Role in Pediatrics and Public Health. G. Cunningham. Critical Reviews in Clinical Laboratory Sciences, 2:45-101, January 1971.

10. Use of Growth Charts for Assessing Progress of Children and Teaching Parents. G. Cunningham. Conference Report, U.S. AID and U.S. HEW, Columbia, MD, May 10-12, 1971.

11. Therapeutic Abortions in California. E.W. Jackson, M. Tashiro, and G. Cunningham. California Medicine, 115:28-33, July 1971.

12. Intermediate Benefit Analysis - Spencer's Dilemma and School Health Services. J. Hazell, F. Hodges, and G. Cunningham. AJPH, 62:560-565, April 1972.

13. Genetics in Relation to Maternal and Child Health and Handicapped Children. G. Cunningham. Maternal and Child Health Practices. Problems, Resources and Methods of Delivery, H. Wallace, E. Gold, and E. Lis, (eds); Springfield, IL: Charles C. Thomas, 1973.

14. Effect of Feeding on Screening for PKU in Infants. V. Dontanville and G. Cunningham.

Pediatrics, 51:531-538, March 1973.

15. Chapter 5 - Phenylketonuria. N. Holtzman, D. Morales, G. Cunningham, and D. Wells. Pediatric Screening Tests, W.K. Frankenburg and B.W. Camp (eds); Springfield, IL: Charles C. Thomas, 1975.

16. Geographic Considerations in Assessment of Children At-Risk in the United States. G. Cunningham. Proceedings, Working Conference on "At Risk Factors and the Health and Nutrition of Young Children", pp. 139-161, Cairo, Egypt, June 23-27, 1975.

17. Intrauterine Growth and Neonatal Risk in California. Monograph, Community Research Institute, University of California at Santa Barbara, January 1976.

18. California's Position on Pregnancy Testing. G. Cunningham. AJPH, 66:7, July 1976.

19. Report - Maternal and Child Health Program. G. Cunningham et al. American Academy of Pediatrics, 1977.

20. Fatal Ectopic Pregnanacy After Sterilization or Abortion - New York, California. E. Hughes, C. Immordino, J. Pakter, and G. Cunningham. Morbidity and Mortality Weekly Report, p. 75, March 4, 1977.

21. Family Planning Services Provided by Obstetricians-Gynecologists in Private Practice, California, 1975. S.L. Solter, D.B. Petitti, R.W. Rochat, and G.C. Cunningham. Advances in Planned Parenthood, 13(2):7-13, 1978.

22. Appendix II - Community Administration and Organization. G. Cunningham. Ambulatory Maternal Health Care and Family Planning Services: Policies, Principles, Practices, F.E.F. Barnes (ed); Crawfordsville, IN: Donnelley & Sons, 1978.

23. Monitoring Perinatal Mortality Rates, California, 1970 to 1976. R. Williams, G. Cunningham, F. Norris, and M. Tashiro. Am. J. Obst. and Gyn., 136(5):559-568, March 1, 1980.

24. Improving Pregnancy Outcome: Effective Approaches in Times of Cost Containment. S.M.C. Payne, H.M. Wallace, G. Cunningham, and D. McNellis. Abstract, Proceedings, APHA 109th Annual Meeting in Los Angeles, California, November 5, 1981.

25. Progress Report of the Expanded Newborn Screening Program in California for the First Ten Months. G. Cunningham, V.L. Mordaunt, L. Greve, and W.R. Centerwall. Abstract, Clinical Research, 30(1):117A, February 1982.

26. Fetal Growth and Perinatal Viability in California. R. Williams, R. Creasy, G. Cunningham, W. Hawes, F. Norris, and M. Tashiro. Obst. and Gyn., 59(5):624-632, May 1, 1982.

27. Genetic Disease Section Activities. G. Cunningham. Proceedings, Bi-regional Conference on MCH Block Grant, Regions 6 & 9. San Diego, p. 283, October 4-6, 1982.

28. Computer Applications for California Newborn Screening Program. E. Gordon, K. Kan, V.L. Mordaunt, T. Follet, and G. Cunningham; Sixth Annual Symposium on Computer Applications in Medical Care, Washington, D.C., November 1982.

29. Chapter 17 - Genetic Programs. G. Cunningham. Maternal and Child Health Practices: Problems, Resources and Methods of Delivery, H. Wallace, E. Gold, and A. Oglesby (eds), second edition, New York: Wiley & Sons, 1982.

30. Nursing Utilization of Teleprinters in California Newborn Screening Program. R. Curtis, N. Fitzmaurice, E. Gordon, V.L. Mordaunt, and G. Cunningham. Proceedings, Congress of Medical Informatics, May 1983.

31. Ethical Issues in Perinatal Care. G. Cunningham. Proceedings, Bi-regional Institute, Regions 8 & 9, San Francisco, July 24-25, 1985.

32. The California AFP Screening Program. L. Lustig, G. Cunningham, and G. Wells. Preventing Low Birthweight and infant Mortality: Programmatic Issues for Public Health Social Workers. C.J. Morton, M.L. Balassone, and S. Guendelman (eds), pp. 187-193, 1987.

33. Early Discharge and Thyroid Screening in Southern California. B. Foley, D. Fisher, L. Shapiro, and G. Cunningham. Advances in Neonatal Screening, B. L. Therrell (ed), p. 36. Elsevier Publishers, 1987.

34. Phenylalanine Level of Newborns in Their First Few Days of Life. G. Cunningham and K. Kan. Advances in Neonatal Screening, B.L. Therrell (ed), p. 179, Elsevier Publishers, 1987.

35. The California Experience with User Fees for Delivery and Development of Genetic Services. G. Cunningham. Proceedings, The Challenge to Provide Genetic Services: Equal Access in a Time of Cost Containment, Boston, MA, May 17-19, 1987.

36. The California Alpha Fetoprotein Screening Program Defended. G. Cunningham. West. J. Med. 147:87, Letter to the Editor, July 1987.

37. Computer Assisted Management of a Regionalized Newborn Screening Program. V. Mordaunt, G. Cunningham, and K. Kan. Proceedings, 21st Hawaii International Conference on System Sciences, pp. 7-16, Kailu-Kona, HI, January 5-8, 1988.

38. Factors Affecting Screening for Congenital Primary Hypothyroidism. K. Kan, G. Cunningham, and V. Mordaunt. Proceedings, 6th National Neonatal Screening Symposium, p. 117, Portland, OR, May 22-25, 1988.

39. Twenty-two Years Later: California's Maternal PKU Program. S. Ahn, G. Cunningham,

and V. Mordaunt. Proceedings, 6th National Neonatal Screening Symposium, p. 139, Portland, OR, May 22-25, 1988.

40. Computer Assisted Management of a Regionalized Newborn Screening Program. V. Mordaunt, G. Cunningham, and K. Kan. Proceedings, 6th National Neonatal Screening Symposium, p. 10, Portland, OR, May 22-25, 1988.

41. CORN National Data Collection on Newborn Screening. G. Cunningham, Proceedings, 6th National Neonatal Screening Symposium, p. 106, Portland, OR, May 22-25, 1988.

42. Laboratory Confirmation of Galactosemia: Experience and New Approaches. W.G. Ng, G. Cunningham, et al. Abstract, Proceedings, 6th National Neonatal Screening Symposium, Portland, OR, May 22-25, 1988.

43. Cardiac Anomalies Associated with Congenital Primary Hypothyroidism. M.B. Hall, K.L. Jones, G. Cunningham. Abstract, Proceedings, 6th National Neonatal Screening Symposium, Portland, OR, May 22-25, 1988.

44. Statewide Genetics Program. G. Cunningham. Proceedings of the Region Nine Regional Institute on Current Major Issues in Maternal and Child Health. San Francisco, July 25-27, 1988.

45. Council of Regional Genetic Networks/Minimum Data Set, G. Cunningham and M.W. Jenckes. Am. Soc. Hum. Gen. Suppl., 3:A212, September, 1988.

46. Should Newborns be Screened for Incurable Diseases? G. Cunningham. Pediatric News, p. 32, September, 1988.

47. Update on Alpha-Fetoprotein Screening. G. Cunningham. The West. J. of Med., 149:449-450, October 1988.

48. Computer Assisted Management of a Regionalized Newborn Screening Program. V.L. Mordaunt, G. Cunningham, and K. Kan. J. of Medical Systems, 12(2):77-88, 1988.

49. California's Experience with Low MS-AFP Results. L. Lustig, G. Cunningham, R. Schonberg, and G. Tompkinson. Am. J. Med. Genet., 31:211-222, 1988.

50. The Diagnosis of Immature Teratoma by Maternal Serum Alpha- Fetoprotein Screening. F.J. Montz, J. Horenstein, L. Platt, G. D'Ablaing, J.B. Schaerth, and G. Cunningham. Obst. and Gyn., 73(3):522-525, March 1989.

51. Computer Assisted Management of a Regionalized Newborn Screening Program. V. Mordaunt, G. Cunningham, and K. Kan. Presented at the Fourth Annual National Symposium on Information Technology, University of South Carolina, April 2-5, 1989.

52. California State Sickle Cell Certification Program. E. Vichinsky, G. Cunningham, et al. Abstract, Proceedings, 14th Annual Meeting of National Sickle Cell Centers, Duke University, North Carolina, April 1989.

53. Measuring the Impact of Genetic Disorders. G. Cunningham. Proceedings, Genetic Services for Underserved Populations, a National Symposium held in Arlington, Virginia, May 1989.

54. An Overview of Barriers to Care. G. Cunningham, Ibid.

55. The Absence of a Relation Between the Periconceptional Use of Vitamins and Neural Tube Defects. J. Mills, G. Cunningham, et al. N. Eng. J. M., 321:430-435, August 1989.

56. Quality Assurance of Demographic Information to Improve Newborn Screening Program Management. V. Mordaunt, K. Kan, P. Gacoscos, and G. Cunningham. Abstract, Proceedings, 7th National Neonatal Screening Symposium, New Orleans, November 1989.

57. Is Second Screening for PKU Good Public Policy? G. Cunningham and K. Kan. Proceedings, 7th National Neonatal Screening Symposium, New Orleans, November 1989.

58. Incidence of congenital hypothyroidism by race and sex. Abstract, in Proceedings, Seventh Neonatal Screening Symposium, New Orleans, November 1989.

59. Defining DNA Diagnostic Tests Appropriate for Standard Clinical Care. R. Lebo, G. Cunningham, M. Simons, and L. Shapiro, Am. J. Hum. Genet., 47:583-590, 1990.

60. Balancing the Individual's Rights to Privacy Against the Need for Information to Protect and Advance Public Health. G. Cunningham. Genetic Screening. From newborns to DNA typing, B. Knoppers and C. Laberge, (eds), Elsevier, 1990.

61. Maternal Serum Alpha-Fetoprotein Screening Activities of State Health Agencies: A Survey. G.Cunningham and K. Kizer. Am. J. Hum. Genet., 47:899-903, 1990.

62. Update on Alpha Fetoprotein Screening in California. G. Cunningham. Western Journal of Medicine, 152:4, April 1990.

63. Periconceptional Use of Multivitamins and the Prevalence of Neural Tube Defects. J. Mills, G. Cunningham, et al. N Engl J Med, 322:15, Letter to Editor, April 1990.

64. Vitamins During Pregnancy and Neural Tube Defects. J. Mills, G. Rhoads, J.L. Simpson, and G. Cunningham, JAMA, 263:20, Letter to the Editor, May 1990.

65. Risk of neural tube defects in relation to maternal fertility and fertility drug use. J. Mills, G. Cunningham, et al; Lancet, 336:103-104, July 14, 1990.

66. Newborn screening for hemoglobinopathy using HPLC. F. Lorey, V. Mordaunt, and G. Cunningham. Proceedings, 8th National Neonatal Screening Symposium, Saratoga Springs, NY, January 1991.

67. Screening for hemoglobinopathies in California using HPLC. Abstract, Proceedings, Eighth Neonatal Screening Symposium, Saratoga Springs, NY, January 1991.

68. Maternal PKU Camp: Four years experience. M. McElroy, V. Mordaunt, and G. Cunningham. Abstract, Proceedings, 8th National Neonatal Screening Symposium, Saratoga Springs, NY, January 1991.

69. Vitamins, folic acid and neural tube defects: Comments on investigations in the United States. J.L. Simpson, J. Mills, G. Cunningham, et al. Prenatal Diagnosis, Vol. 11, 1991.

70. Reply to Lippman. G. Cunningham, Am. J. Hum. Genet., 48:6, Letter to the Editor, June 1991.

71. Second-trimester Maternal Serum Alpha-fetoprotein Levels and the Risk of Subsequent Fetal Death. D.K. Waller, L. Lustig, G. Cunningham, M. Golbus, E. Hook. N Engl J Med, 325:6-10, 1991.

72. Development of a National Genetic Services Database. F.J. Meaney, G. Cunningham, and S. Riggle. Proceedings, Symposium on Computer Applications in Medical Care by the American Medical Information Association, Washington, D.C., November 17, 1991.

73. Genetic Heterogeneity in Neural Tube Defects. J.L. Simpson, J. Mills, G. Cunningham, et al. Ann. Genet., 34:279-286, 1991.

74. Distribution of human immunodeficiency virus type 1 infection in childbearing women in California. G. Cunningham, F.J. Capell, et al. AJPH, 82(2), February 1992.

75. The Council of Regional Networks for Genetic Services (CORN) Newborn Screening Reports: Methods and Results. S. Riggle and G. Cunningham. Proceedings, 9th National CORN Meeting, Raleigh, NY, April 7-10, 1992.

76. Differentiation of homozygous E vs Hb E/Beta thalassemia using HPLC results from newborn screening. Abstract, Proceedings, 9th Neonatal Screening Symposium, Raleigh, NC, April 1992.

77. The California Maternal Serum α-Fetoprotein Screening Program: The role of ultrasound in the detection of Spina Bifida. L. Platt, L. Feuchtbaum, R. Filly, L. Lustig, M. Simon, G. Cunningham. Am. J. Obst. and Gyn., 166(5):1328-29, May 1992.

78. California Newborn Screening Program - A Case Study. G. Cunningham. Background paper prepared for the Institute of Medicine Committee on Assessing Genetics Risks, Washington, DC, July 1992.

79. Statewide Governmentally Administered Prenatal Blood Screening - A Case Study in Cost Effective Prevention. G. Cunningham. Background paper prepared for the Institute of Medicine Committee on Assessing Genetics Risks, Washington, DC, July 1992.

80. Birth Prevalence of Primary Congenital Hypothyroidism by Sex and Ethnicity. F. Lorey and G. Cunningham. Human Biology, 64(4):531-538, August 1992.

81. Gene frequencies and birth prevalence of hemoglobin disorders by ethnic group in a universal testing program. Abstract in Am J Hum Gen, 1992.

82. Race-specific median MSAFP values by gestational age. G. Tompkinson, G. Cunningham. Abstract in Am J Hum Gen, 1992.

83. Reply to Milunsky. J.L. Simpson, G. Cunningham, et al. Prenatal Diagnosis, 12:(in press), Letter to the Editor, 1992.

84. Phenylketonuria and other inherited metabolic defects. G. Cunningham. Antenatal and Neonatal Screening, 2d. ed., N. Wald,(ed), Oxford University Press, (in press).

85. Genetic heterogeneity and neural tube defects: relevance to folate responsiveness. J.L. Simpson, G. Cunningham, et al. Proceedings, XIII European Congress on Perinatal Medicine, Amsterdam, May 1992 (in press).

86. Providers and Consumers of Prenatal Genetic Testing Services: What do the National Data Tell Us? F. J. Meaney, S. Riggle, G. Cunningham. Fetal Diagnosis and Therapy, T1-257, (in press).

87. Detection of Hb E/β-Thalassemia versus Homozygous EE Using High-Performance Liquid Chromatography Results from Newborns. F. Lorey, G. Cunningham, et al. Biochemical Medicine and Metabolic Biology, 49:67-73, 1993.

88. Prenatal Genetic Services: Toward a National Data Base. F. J. Meaney, S.M. Riggle, G. Cunningham et al. Clinical Obstetrics and Gynecology, 36:3, 510-520, September 1993.

89. Prenatal screening to reduce the need for amniocentesis in women age 35 and older. JE Haddow, G Palomaki, G Cunningham et al. Am J Hum Gen, 53:3, p4, Sept. 1993.

90. Elevated MSAFP and Chromosome Abnormalities. L.B. Feuchtbaum, L.S. Lustig, G. Cunningham, et al. Abstract in Proceedings, American Society of Human Genetics, New Orleans, October 1993.

91. A comparison and evaluation of two national surveys of genetic services. F.J. Meaney, S.M. Riggle, G. Cunningham, et al. Abstract in Proceedings, American Society of Human Genetics, New Orleans, October 1993.

92. Differential protein production by genotype in different forms of sickle cell disease detected in neonates. F. W. Lorey, G. Cunningham, B. Lubin et al. Abstract in Proceedings, American Society of Human Genetics, New Orleans, October 1993.

93. Incidence of sudden infant death syndrome in infants with sickle cell trait. D. Gozal, F.

Lorey, G.Cunningham et al. The Journal of Pediatrics, 211-214, February 1994.

94. Are obese women at higher risk for producing malformed offspring? K.D. Waller, J.L.Mills, G.Cunningham et al. Am J Obstet Gynecol, 541-548, February 1994.

95. Obtaining consent of parents for immunization. Letter to the Editor. G. Cunningham. Arch Dis Child, 1994 (in press).

96. Effect of specimen collection method on newborn screening for PKU. F. W. Lorey, G. Cunninghan. Screening, 3:57-65, 1994.

97. Hb Oleander, a relatively common alpha chain mutant detected during newborn screening can be confused with sickle hemoglobin. F. Lorey, G. Cunningham et al. Submitted to 19th Meeting of National Sickle Cell Program, New York, March 23-26, 1994.

98. Validity of screening early collected newborn specimens for phenylketonuria using a fluorometric method. K. Jew, K. Kan, R. Koch, G. Cunningham. Screening, 3:1; 1-9, March 1994.

99. Reducing the need for amniocentesis in women 35 years of age or older by the use of serum markers for screening. J.E. Haddow, G.E. Palomaki, G. Cunningham et al. N Eng J Med 330:1114-1118 April 1994.

100. Universal screening for hemoglobinopathies using high performance liquid chromatography. FW Lorey, F Shafer, G Cunningham, et al. Eur J Human Genetics 2:262-271, 1994.

101. Universal screening for hemoglobinopathies by HPLC in California. In New Horizons in Neonatal Screening, JP Farriaux and JL Dhondt, eds. Elsevier Science B.C. Excerpta Medica, Amsterdam, pp 203-206. 1994.

102. Serial phenylalanine levels in affected and unaffected PKU siblings. Abstract in Proceedings, 10th National Neonatal Screening Symposia, Seattle, WA, June 7-11, 1994.

103. Reply to Haddow and Palomaki letter to the editor, Is Maternal Obesity a Risk Factor for Open Neural Tube Defects? Am J Obstet Gynecol, 172:1, 246-247, Jan.1995.

104. California's Public Health Policy on Preventing Neural Tube Defects by Folate Supplementation. West J Med 162:265-267, March 1995.

105. Relative hemoglobin percentages in newborns with differing final diagnoses: sickle cell anemia, sickle beta thalassemia, sickle/HPFH, and sickle carriers. FW Lorey, GC Cunningham. Abstract in Proceedings, 20th Annual meeting of the National Sickle Cell Program, Boston, MA, March 1995.

106. Results of screening for phenylketonuria using a lower cutoff value in early collected

specimens. JJ Arnopp, FW Lorey, GC Cunningham, et al. J International Soc Neonatal Screening 3: 193-199, 1995.

107. Frequency of medium-chain ACYL-COA dehydrogenase (MCAD) deficiency among California children dying of sudden infant death syndrome (SIDS) or liver diesase. 2-tiered analysis of NBS specimens. LL McCabe, F Lorey, G Cunningham et al. Pediatric Research 37:4, A156, April 1995.

108. Fetal Karyotyping for Chromosome Abnormalities After an Unexplained Elevated Maternal Serum Alpha Fetoprotein Screening. L.B.Feuchtbaum, G. Cunningham, et al. Obstetrics & Gynecology 86:2 August 1995.

109. Distribution of the HB-E allele and HB-3 related hemoglobinopathy and β-thalassemia in several Asian populations. Abstract. F Lorey, G Cunningham, Am J Hum Gen 57:4 Suppl., n. 1844, 1995.

110. Code of Ethical Principles for Genetics Professionals: An Explication. R. C. Baumiller, G. Cunningham, et al. AJMG 65:179-183, 1996.

111. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. F. Lorey, J. Arnopp, G. Cunningham. Genetic Epidemiology 13:501, 501-512, 1996.

112. Newborn screening for congenital hypothyroidism: false positive rates in the first 48 hours of life. J. Arnopp, F. Lorey, G. Cunningham. Abstract, International Society for Neonatal Screening, Boston, Oct. 21-24, 1996.

113. The Association Between Maternal Serum Alpha-Fetoprotein and Preterm Birth, Small for Gestational Age Infants, Preeclampsia, and Placental Complications. K. Waller, L. Lustig, G. Cunningham, L. Feuchtbaum, E. Hook. Obstetrics and Gynecology, 88:5, p. 816-22 1996.

114. Folic Acid Supplementation: Is it Really Working to Reduce NTDs? M. Thomson, L. Robinson, R. Currier, D. Tompkinson, G. Cunningham. Abstract, AJMG, Feb-Mar 1997 meeting.

115. A Public Health Perspective on the Control of Predictive Screening for Breast Cancer, Health Matrix: Journal of Law-Medicine 7:1, 31-48,1997.

116. Analysis of the First Year of the Expanded AFP Program. G. Cunningham. In Proceedings of the International Conference on Down Syndrome Screening Policy and Economic Evaluation, March 6-8, 1997, in Athens, Greece. (Published 1999.)

117. Vitamin A and birth defects. J. Mills, J Simpson, G. Cunningham, M. Conley, G. Rhoads. Am J Obstet Gynecol, 177:1, 31-36, 1997.

118. Double and triple positive results from maternal serum screening. R. Currier, S. Goldman, M. Lassman, G. Cunningham. Abstract, ASHG Proceedings, Baltimore,

October 1997.

119. Racial differences in the rate of neural tube defects: The California AFP Screening Program, 1990-1994. L. Feuchtbaum, R. Currier, S. Riggle, M. Roberson, G. Tompkinson, F. Lorey, M. Lassman, G. Cunningham. ASHG Proceedings, Annual Meeting, October 28-November 1, 1997, Baltimore.

120. Chromosome abnormalities before birth: 1) factors associated with decisions to terminate autosomal trisomy pregnancies; 2) more data on the natural history of pregnancies not electively terminated. E.B. Hook, G. C. Cunningham, R.J. Currier, S. K. Goldman, F. W. Lorey, et al. Asbtract in AJHG v. 61, (suppl.) Annual Meeting, October 1997.

121. Newborn screening for hemoglobin H disease using an automated HPLC system. F. Lorey, E. Vichinsky, G. Cunningham, et al. Abstract in Blood, Journal of the American Society of Hematology, v. 90, no. 10, Suppl. 1, November 1997.

122. Mortality Among Children with Sickle Cell Disease Identified by Newborn Screening During 1990-1994 -- California, Illinois, and New York. G. Cunningham, F. Lorey, et al. MMWR, v. 47, no. 9, March 1998.

123. Use of phenylalanine to tyrosine ratio as determined by tandem mass spectrometry to improve screening for phenylketonuria of early discharge specimens collected in first 24 hours. D. Chace, J. Sherwin, S. Hillman, F. Lorey, G. Cunningham. Clinical Chemistry, v. 44, n. 12, 1998.

124. Impact of Asian Immigration on thalassemia in California. F. Lorey, G. Cunningham. In Annals of the New York Academy of Sciences, Cooley's Anemia, Seventh Symposium, June 30, 1998 v. 850, ed. Alan R. Cohen.

125. Distribution of hemoglobin F, A, S, C, E and D quantities in newborn screening specimens. J. Eastman, F. Lorey, J. Arnopp, R. Currier, J. Sherwin, G. Cunningham. (Submitted December 1998.)

126. Digit preferences in the first day of the last menstrual period. D. K. Waller, W. D. Spears, Y. Gu, G. Cunningham. To be submitted to Pediatric and Perinatal Epidemiology.

127. Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference. JE Haddow, G Palomaki, G Cunningham, et al. Genetics in Medicine, v. 1, n. 4, 1999. Also published in J. Med. Screen, 6, 1999.

128. Neural Tube Defect Prevalence in California (1990-1994): Eliciting Patterns by Type of Defect and Maternal Race/Ethnicity. L. Feuchtbaum, R. Currier, S. Riggle, M. Roberson, F. Lorey, G. Cunningham. Genetic Testing, v. 3, n. 3, 1999.

129. Risk factors for congenital hypothyroidism: an investigation of infant's birth weight,

ethnicity and gender, California, 1990 to 1998. (in press) DK Waller, F Lorey, G Cunningham et al.

130. Population screening, molecular confirmation and birth prevalence of hemoglobin H disease in CA newborns. F Lorey, B Lubin, J Sherwin, G Cunningham et al. (in press)

131. The genetics revolution: Ethical, legal, and insurance concerns. G. Cunningham, Postgraduate Medicine, v. 108, n. 1, July 2000.

132. Assessing number-specific error in the recall of onset of last menstrual period. D.K. Waller, WD Spears, G Cunningham, Paediatric and Perinatal Epidemiology v. 14, 263-267, 2000.

133. Regulating Genetic Services. G. Cunningham. Encylclopedia of Ethical, Legal, and Policy Issues in Biotechnology, v. 1, John Wiley & Sons, 2000.

134. Book review, "Engineering the Human Germline: An Exploration of the Science and Ethics of Altering the Genes We Pass To Our Children," Gregory Stock and John Campbell, eds., NY, Oxford University Press, 2000, in N Eng J Med, v. 349, n. 19, 2000.

135. Use of phenylalanine/tyrosine ratio to test newborns for PKU in a large public health screening program. JW Eastman, JE Sherwin, F Lorey, G Cunningham et al. J Med Screen, v. 7, 2000.

136. Are estimates of gestational age from pregnant women who report non-preferred digits for the first day of the LMP more accurate? A comparison of estimates of gestational age based on LMP and early ultrasound examinations among 7,231 live births. DK Waller, WD Spears, Y Gu, G Cunningham. (In press.)

137. Letter to the editor re Farrell et al article, "Is Public Health Ready for Genetics? An Unanswered Question," in Feb. 2001 issue of Archives and editorial by Holtzman, in press.

138. The science and politics of screening newborns. The New England Journal of Medicine, Vol. 14, April 4, 2002.

h:gcc:gen:gcccv
08/07/02